Cann Group Limited

Profile narrative

Cann Group Limited is an Australian company engaged in the production and supply of medicinal cannabis products. It holds licences issued by the Office of Drug Control to cultivate, manufacture and distribute cannabis‑based medicines for therapeutic use. The company’s product portfolio includes dried flower, standardized oils, capsules and other formulations that meet Good Manufacturing Practice (GMP) standards. These products are supplied to patients within Australia through the Special Access Scheme and Authorised Prescriber pathways, and the firm also pursues export opportunities in jurisdictions where medicinal cannabis is permitted. Its operations are focused on serving the medical market rather than recreational use, emphasizing compliance with pharmaceutical‑grade quality and safety requirements.

Cann Group Limited distinguishes itself by specialising in GMP‑certified cultivation and extraction processes that aim to deliver consistent cannabinoid profiles for clinical applications. The company positions itself within the Australian medicinal cannabis sector as one of the few licensed producers with integrated indoor cultivation and downstream processing capabilities. Its notable competencies include seed‑to‑sale tracking, analytical testing for potency and contaminants, and formulation development tailored to specific therapeutic indications. Structurally, Cann Group Limited is a publicly listed entity traded on the Australian Securities Exchange under the ticker CAN, with its headquarters located in Australia. The firm experienced a significant cyber fraud incident in February 2021, when an unauthorized $3.6 million payment was made to a fraudulent overseas contractor during a construction project. Following the event, Cann Group undertook immediate IT security enhancements, cooperated with its bank and insurers, and reported the matter to law‑enforcement agencies in Victoria, the Netherlands, Hong Kong and relevant drug regulators. Although the incident contributed to a temporary share‑price decline and highlighted existing cash‑flow pressures, the company retained substantial cash reserves and continued to pursue its medicinal cannabis business objectives.

Incidents

1 incident linked to this organisation.